Relieves inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses. Sold as Cordran, Cordran Sp. Every FDA application for this active ingredient: 3 branded and 5 generic.
As of Nov 15, 2026, FDA lists 8 applications for Flurandrenolide (sold as Cordran, Cordran Sp), first approved Mar 19, 1963, with 0 new uses approved and 0 published complete response letters.
| Cordran | Part D | $2.4M | -30% | 1,246 |
| Flurandrenolide | Part D | $65K | -10% | 149 |
| Study | Phase | Status | Posted |
|---|---|---|---|
| Haelan 951 for Menopause Symptoms in Peri- and Postmenopausal WomenMenopause, Menopause Hot Flashes · Spectrum Clinical Research, LLC | Not applicable | Recruiting | Aug 6, 2026 |
| Mar 19, 1963 | CordranNDA 13790 · New dosage form | Ina Pharms | 12 | Discontinued |
| Oct 18, 1965 | Cordran, Cordran SpNDA 12806 · New molecular entity | Ina Pharms | 19 | Discontinued |
| Jul 29, 1969 | CordranNDA 16455 · New dosage form | Almirall | 12 | Marketed |
| Apr 29, 1982 | FlurandrenolideANDA 87203 | Alpharma US Pharms | 2 | Discontinued |
| Apr 13, 2016 | FlurandrenolideANDA 205342 | Chartwell Rx | 0 | Discontinued |
| Aug 30, 2016 | FlurandrenolideANDA 207133 | Padagis Israel | 0 | Marketed |
| Dec 22, 2016 | FlurandrenolideANDA 205343 | Chartwell Rx | 0 | Discontinued |
| Dec 30, 2016 | FlurandrenolideANDA 207851 | Teligent | 0 | Marketed |
Applications, approvals and products come from FDA's Drugs@FDA data files, refreshed weekly, grouped by active ingredient as FDA spells it. Complete response letters are FDA's published letters. Medicare spending is CMS's Part D and Part B dashboard, matched to this ingredient by generic name; shortages are FDA's shortage list, matched by application number; clinical trials are ClinicalTrials.gov studies naming the ingredient as an intervention, refreshed daily; safety programs are FDA's REMS list, matched by application number or, for shared programs, by ingredient. Drugs@FDA
